Evidence map›Paper›PMID 42693412›Full record

ArticleBMC microbiology2026

Detection of carbapenem resistance mechanisms in difficult-to-treat Pseudomonas aeruginosa clinical isolates from a tertiary care hospital in Egypt.

Dalia Salem, Manar Zaiton, Ahmed El-Shenawy, Heba Dahroug, Samah El-Dein, Doaa Gamal, Azza Ali Althoqapy, Amr Aw Mohamed, Mohamed A Shemis, Manal Diab and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dalia SalemMicrobiology Department, Theodor Bilharz Research Institute (TBRI), P.O box 12411, 30 Imbaba, Giza, Egypt. drdaliasalem@gmail.com.ORCID https://orcid.org/0000-0003-4880-2240
Manar ZaitonMicrobiology Department, Theodor Bilharz Research Institute (TBRI), P.O box 12411, 30 Imbaba, Giza, Egypt.
Ahmed El-ShenawyMicrobiology Department, Theodor Bilharz Research Institute (TBRI), P.O box 12411, 30 Imbaba, Giza, Egypt.
Heba DahrougMicrobiology Department, Theodor Bilharz Research Institute (TBRI), P.O box 12411, 30 Imbaba, Giza, Egypt.
Samah El-DeinMicrobiology Department, Theodor Bilharz Research Institute (TBRI), P.O box 12411, 30 Imbaba, Giza, Egypt.
Doaa GamalMicrobiology Department, Theodor Bilharz Research Institute (TBRI), P.O box 12411, 30 Imbaba, Giza, Egypt.
Azza Ali AlthoqapyMedical Microbiology and Immunology, Faculty of Medicine for Girls, Al- Azhar University, Cairo, Egypt.
Amr Aw MohamedBiochemistry and Molecular Biology Department, Theodor Bilharz Research institute (TBRI), P.O box 12411, 30 Imbaba, Giza, Egypt.
Mohamed A ShemisBiochemistry and Molecular Biology Department, Theodor Bilharz Research institute (TBRI), P.O box 12411, 30 Imbaba, Giza, Egypt.
Manal DiabMicrobiology Department, Theodor Bilharz Research Institute (TBRI), P.O box 12411, 30 Imbaba, Giza, Egypt.
Soheir S MakladMedical Microbiology and Immunology, Faculty of Medicine for Girls, Al- Azhar University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe increasing incidence of carbapenem-resistant Pseudomonas aeruginosa (CRPA) poses a significant global health concern, particularly with the emergence of difficult-to-treat resistance (DTR), which seriously restricts therapeutic options. Therefore, we aimed to characterize DTR-PA isolates among the studied CRPA; regarding their resistance mechanisms to carbapenems and their antimicrobial susceptibility profiles.

methodsFifty-two non-duplicate CRPA isolates were collected from clinical specimens. Antimicrobial susceptibility testing was performed using disc diffusion and VITEK2 compact system. Isolates were classified as multidrug-resistant P. aeruginosa (MDR-PA), extensively drug-resistant P. aeruginosa (XDR-PA), and DTR-PA. Conventional PCR was used to detect carbapenemase genes (bla

resultsFifty-two (52) CRPA isolates were categorized according to resistance phenotype into three main groups where 46% were identified as DTR-PA, 38% as XDR-PA, 8% as MDR-PA and 8% remained uncategorized. In DTR-PA, carbapenemase genes were detected in 92% of isolates with bla

conclusionsDifficult to treat Pseudomonas aeruginosa is highly prevalent among CRPA isolates in our setting and is caused by multiple resistance mechanisms, particularly bla

Indexed as

Anti-Bacterial AgentsCarbapenemsPseudomonas aeruginosaPseudomonas InfectionsBacterial Outer Membrane ProteinsBacterial Proteinsbeta-LactamasesDrug Resistance, Multiple, BacterialEgyptHumansMembrane Transport ProteinsMicrobial Sensitivity TestsPorinsTertiary Care CentersAnti-Bacterial AgentsBacterial Outer Membrane ProteinsBacterial Proteinsbeta-LactamasescarbapenemaseCarbapenemsMembrane Transport ProteinsOprD protein, Pseudomonas aeruginosaPorinsbla NDMCarbapenemasesCarbapenem resistant Pseudomonas aeruginosa (CRPA)Difficult-to-treat resistance (DTR)Efflux pumpsMexBMexYMultidrug resistance (MDR)OprD.

Identifiers

PMID42693412
PMCPMC13543481

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.